Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
J Korean Med Sci. 2013 Jul;28(7):1005-14. doi: 10.3346/jkms.2013.28.7.1005. Epub 2013 Jul 3.
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-κB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-κB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-κB expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-κB value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P=0.013). Similarly, in EGFR wild-type patients treated with EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P=0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI.
转谷氨酰胺酶 2（TG2）是一种交联酶，参与药物耐药和核因子 κB（NF-κB）的组成性激活。我们研究了 120 例非小细胞肺癌（NSCLC）患者的 TG2 和 NF-κB 表达与治疗效果的关系：102 例为腺癌，18 例为其他组织学类型。所有患者均接受手术治疗；88 例接受辅助化疗，其中 28 例接受铂类双联化疗作为一线治疗，29 例接受表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKI）治疗。患者的 TG2 和 NF-κB 表达值采用半定量方法计算。TG2 值的中位数为 50（范围，0-300），NF-κB 值的中位数为 20（范围，0-240）。低 TG2 组和高 TG2 组之间的无病生存期没有差异。在接受姑息性铂类双联化疗的患者中，低 TG2 组的无进展生存期（PFS）长于高 TG2 组（11.0 与 7.0 个月；P=0.330）。在接受 EGFR-TKI 治疗的患者中，低 TG2 组的 PFS 也长于高 TG2 组（11.0 与 2.0 个月；P=0.013）。同样，在接受 EGFR-TKI 治疗的 EGFR 野生型患者中，低 TG2 表达患者的 PFS 更长（9.0 与 2.0 个月；P=0.013）。TG2 表达水平可预测接受 EGFR-TKI 治疗的 NSCLC 患者的 PFS。
